All results

15 results for randomized double blind placebo controlled study erlotinib or placebo patients

• Adaptive COVID-19 Treatment Trial (ACTT)

  This study is an adaptive, randomized, double-blind, placebo-controlled trial to evaluate the safety and efficacy of novel therapeutic agents in hospitalized…

  Ages

  18 Years - 99 Years

  Sexes

  All

• CC-90001 in Subjects With Idiopathic Pulmonary Fibrosis

  This is a Phase 2, multicenter, multinational, randomized, double-blind, placebo-controlled study evaluating the efficacy, safety, pharmacokinetics (PK),…

  Ages

  40 Years - N/A

  Sexes

  All

• CTD-TCNPC-301

  A prospective, randomized, double-blind, placebo controlled, multi-center therapeutic study for patients age 3 and older with confirmed diagnosis of Niemann…

  Ages

  3 Years - N/A

  Sexes

  All

• FASTEST Trial

  The objective of the rFVIIa for Acute Hemorrhagic Stroke Administered at Earliest Time (FASTEST) Trial is to establish the first treatment for acute…

  Ages

  18 Years - 80 Years

  Sexes

  All

• GALACTIC-1

  This is a randomized, double-blind, placebo-controlled phase 2b trial in subjects with IPF (idiopathic pulmonary fibrosis) investigating the efficacy and…

  Ages

  40 Years - N/A

  Sexes

  All

• GCAptAIN

  This is a phase III study of efficacy and safety of secukinumab versus placebo, in combination with glucocorticoid taper regimen, in patients with giant cell…

  Ages

  50 Years - N/A

  Sexes

  All

• NIH AIM 2 - Low Dose Pioglitazone in NASH

  To determine the safety and efficacy of low-dose pioglitazone (15 mg per day) on liver histology in in patients with T2DM with biopsy-proven nonalcoholic…

  Ages

  21 Years - 75 Years

  Sexes

  All

• Protocol TN-28

  A multi-center, placebo-controlled, double blind, 2:1 randomized control clinical trial testing low-dose ATG vs. placebo in subjects with a 2 year 50% risk of…

  Ages

  12 Years - 34 Years

  Sexes

  All

• RAISE

  This study will evaluate the effectiveness and safety of an investigational product (IP), intravenous (IV) ganaxolone, to treat participants with status…

  Ages

  12 Years - N/A

  Sexes

  All

• RECOVER VITAL

  This study is a platform protocol designed to be flexible so that it is suitable for a wide range of settings within health care systems and in community…

  Ages

  18 Years - N/A

  Sexes

  All